Naumenko S E, Naumenko K S, Pokrovskiĭ M G, Kim S F
Anesteziol Reanimatol. 2004 Jul-Aug(4):15-9.
Seventy-three patients with ischemic heart disease (IHD), who underwent coronary artery bypass grafting with artificial circulation (AC), were examined within a prospective randomized study. The patients were randomized between three groups. The group-1 patients were administered trasilol (T) according to the below scheme: 1 mln KIU from patient's admission to the surgery room to the time the skin incision is made plus 2 mln KIU from the moment the surgical approach is preformed to the beginning of AC. KIU was added to the artificial circulation apparatus (ACA) when it was initially filled (total T dose of 6 min KIU). T was administered in the group-2 patients similarly to the scheme used in group 1; however, it was not added to the ACA (total T dose of 3 mln KIU). And T was not used at all in the group-3 patients. The dose of mezatone administered at the AC stage was reliably higher in groups 3 and 4 versus group 1 (p < 0.05 and p < 0.1, respectively). Doses of mezatone that were used for the vasopressin management did not differ significantly between the groups after surgery. A statistically more significant increase of stroke index (deltaSI) and a decrease of general peripheral vascular resistance (GPVR--deltaGPVR) were registered in 12 hours after surgery in group 3 versus group 1, p < 0.05 and p < 0.01, respectively. The negative deltaGPRV was also more pronounced versus the parameters observed in group 1 and 2 (p < 0.01 and p < 0.02, respectively). Therefore, T, when used at 6 mln KIU in AC, provides for a smaller-scope vasopressin management in AC. And, when it is used before AC at 3 mln KIU, T dose not diminish the dose of vasopressin management in AC. The intraoperative use of T (6 or 3 mln KIU) arrests a pronounced decreased postoperative deltaGPRVR and an increased postoperative CI irrespective of a dose.
在一项前瞻性随机研究中,对73例接受人工循环冠状动脉搭桥术的缺血性心脏病(IHD)患者进行了检查。患者被随机分为三组。1组患者按照以下方案给予抑肽酶(T):从患者进入手术室到皮肤切开时给予100万KIU,从手术开始到人工循环(AC)开始时给予200万KIU。当人工循环装置(ACA)最初填充时加入KIU(总T剂量为600万KIU)。2组患者给予T的方案与1组相同;然而,未将其加入ACA(总T剂量为300万KIU)。3组患者根本未使用T。在AC阶段给予的美托咪啶剂量在3组和4组中确实高于1组(分别为p<0.05和p<0.1)。术后各组用于血管升压素管理的美托咪啶剂量无显著差异。与1组相比,3组术后12小时的中风指数(deltaSI)有统计学意义的更显著增加,全身外周血管阻力(GPVR--deltaGPVR)降低,分别为p<0.05和p<0.01。与1组和2组观察到的参数相比,负deltaGPRV也更明显(分别为p<0.01和p<0.02)。因此,在AC中以600万KIU使用T时,AC中血管升压素管理的范围较小。并且,当在AC前以300万KIU使用时,T剂量不会减少AC中血管升压素管理的剂量。无论剂量如何,术中使用T(600万或300万KIU)均可阻止术后deltaGPRVR的显著降低和术后CI的增加。